High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European organization for research and treatment of cancer lymphoma group phase II trial 20962

被引:219
|
作者
Poortmans, PMP
Kluin-Nelemans, HC
Haaxma-Reiche, H
Van't Veer, M
Hansen, M
Soubeyran, P
Taphoorn, M
Thomas, J
Van den Bent, M
Fickers, M
Van Imhoff, G
Rozewicz, C
Teodorovic, I
van Glabbeke, M
机构
[1] Dr Bernard Verbeeten Inst, NL-5000 LA Tilburg, Netherlands
[2] Univ Groningen Hosp, Groningen, Netherlands
[3] Daniel Hoed Klin, Rotterdam, Netherlands
[4] Univ Med Ctr, Utrecht, Netherlands
[5] Atrium Med Ctr, Heerlen, Netherlands
[6] Univ Med Ctr, Leiden, Netherlands
[7] Rigshosp, DK-2100 Copenhagen, Denmark
[8] Inst Bergonie, Bordeaux, France
[9] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[10] European Organizat Res & Treatment Canc Data Ctr, Brussels, Belgium
关键词
D O I
10.1200/JCO.2003.03.108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy combined with radiotherapy (RT) for patients with non-AIDS-related primary CNS lymphoma (PCNSL) treated in a multicenter setting. Patients and Methods: Treatment consisted of two cycles of MBVP (MTX 3 g/m(2) days 1 and 15, teniposide 100 mg/m(2) days 2 and 3, cormustine 100 mg/m(2) day 4, methylprednisolone 60 mg/m(2) days 1 to 5, and two intrathecal injections of MTX 15 mg, cytarabine 40 mg, and hydrocortisone 25 mg) followed by 40 Gy of RT. Primary end points were response and safety of this regimen. Results: Twelve centers included 52 patients who were all analyzed on an intent-to-treat basis. Median follow-up of all patients was 27 months. One patient progressed and died before treatment, and five patients died during treatment. Four patients received RT after one cycle of chemotherapy, and 42 patients completed the entire treatment. Hematologic grade 3 and 4 toxicity was seen in 78% of patients for leukocytes and 24% of patients for platelets. The overall response rate of all 52 patients was 81%. Two patients who did not fulfill the criteria of objective response survived more than 1 year; one of them is still alive without disease. Eighteen patients died; 11 deaths were a result of tumor, five were probably treatment-related, one was caused by late leukoencephalopathy, and one was a result of intercurrent disease. Median estimated overall survival was 46 months. Conclusion: MBVP followed by RT for PCNSL has a high response rate. However, the 10% toxic death rate during treatment in a multicenter setting underlines the need for highly specialized care. (C) 2003 by American Society of Clinical Oncology.
引用
收藏
页码:4483 / 4488
页数:6
相关论文
共 50 条
  • [1] Dose MTX-based chemotherapy followed by consolidating radiotherapy in Non-Aids related Primary Central Nervous System Lymphoma.
    Kluin-Nelemans, JC
    Poortmans, P
    Haaxma-Reicher, H
    van't Veer, MB
    Hansen, M
    Taphoorn, MJ
    Thomas, J
    Soubeyran, P
    Fickers, M
    Loosveld, OJ
    Roerdink, HT
    van den Bent, MJ
    van Imhoff, GW
    Teodorovic, I
    Rozewicz, C
    Van Glabbeke, MM
    Raemaekers, JM
    [J]. BLOOD, 2002, 100 (11) : 776A - 777A
  • [2] High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma
    Freeman, Tracelyn
    Legasto, Carlo S.
    Schickli, M. Alexandra
    McLaughlin, Eric M.
    Giglio, Pierre
    Puduvalli, Vinay
    Gonzalez, Javier
    [J]. NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [3] Radiomic prediction for durable response to high-dose methotrexate-based chemotherapy in primary central nervous system lymphoma
    Li, Haoyi
    Xiong, Mingming
    Li, Ming
    Sun, Caixia
    Zheng, Dao
    Yuan, Leilei
    Chen, Qian
    Lin, Song
    Liu, Zhenyu
    Ren, Xiaohui
    [J]. CANCER MEDICINE, 2024, 13 (17):
  • [4] Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy
    Ekenel, Meltem
    Iwamoto, Fabio M.
    Ben-Porat, Leah S.
    Panageas, Katherine S.
    Yahalom, Joachim
    DeAngelis, Lisa M.
    Abrey, Lauren E.
    [J]. CANCER, 2008, 113 (05) : 1025 - 1031
  • [5] Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy
    Steinbeck, J. A.
    Stuplich, M.
    Blasius, E.
    Pels, H.
    Glas, M.
    Schlegel, U.
    Herrlinger, U.
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2011, 18 (11) : 1554 - 1555
  • [6] PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: HIGH-DOSE METHOTREXATE PLUS RADIOTHERAPY, BETTER TREATMENT FOR ALL?
    Gonzalez-Domingo, M.
    Gonzalez-San Segundo, C.
    Menarguez, J.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S361 - S362
  • [7] Predicting prognosis outcomes of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment using lipidomics
    Zhong, Yi
    Zhou, Liying
    Xu, Jingshen
    Huang, He
    [J]. NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [8] PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: HIGH-DOSE METHOTREXATE PLUS RADIOTHERAPY, BETTER TREATMENT FOR ALL?
    Gonzalez-Domingo, M.
    Gonzalez-San Segundo, C.
    Menarguez, J.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2010, 96 : X - X
  • [9] High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma
    Gerard, Lauren M.
    Imrie, Kevin R.
    Mangel, Joy
    Buckstein, Rena
    Doherty, Mary
    Mackenzie, Robert
    Cheung, Matthew C.
    [J]. LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1882 - 1890
  • [10] Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients
    Ferreri, AJM
    Reni, M
    Dell'Oro, S
    Ciceri, F
    Bernardi, M
    Camba, L
    Ponzoni, M
    Terreni, MR
    Tomirotti, M
    Spina, M
    Villa, E
    [J]. ONCOLOGY, 2001, 60 (02) : 134 - 140